Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
Autorzy:
Taieb J; Department of Gastroenterology and Digestive Oncology, European Hospital Group Georges-Pompidou, Paris, France. . Price T; Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Woodville South, South Australia, Australia. Vidot L; Servier, Suresnes, Paris, France. Chevallier B; Servier, Suresnes, Paris, France. Wyrwicz L; Department of Oncology and Radiotherapy, Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw National Cancer Research Institute, Warsaw, Poland. BachetJB; Department of Hepatogastroenterology, University Hospital Pitie Salpetriere, Paris, France.; Sorbonne University, Paris, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jan 27; Vol. 23 (1), pp. 94. Date of Electronic Publication: 2023 Jan 27.
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.
Autorzy:
Javed S; Department of Medical Oncology, Centre Oscar Lambret, F-59000, Lille, France.; Department of Medical Oncology, Centre Hospitalier de Valenciennes, F-59300, Valenciennes, France. Benoist S; Department of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris-Sud University, Paris, France. Devos P; University of Lille, CHU Lille, F-59000, Lille, France. Truant S; Department of Digestive Surgery and Transplantation, CHU Lille, F-59000, Lille, France. Guimbaud R; Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France. Lièvre A; Department of Gastroenterology, CHU Pontchaillou, Rennes 1 University, Rennes, France. Sefrioui D; Digestive Oncology Unit, Department of Hepatogastroenterology, Rouen University Hospital, Normandie Université, UNIROUEN, Inserm 1245, IRON group, Rouen, France. Cohen R; Medical Oncology Department, Saint-Antoine Hospital, Sorbonne University, AP-HP, F-75012, Paris, France. Artru P; Department of Gastroenterology, Jean Mermoz Hospital, Lyon, France. Dupré A; Department of Surgical Oncology, Leon Berard Cancer Center, UNICANCER, Lyon, France. BachetJB; Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France. de la Fouchardière C; Medical Oncology Department, Centre Leon Berard, Lyon I University, Lyon, France. Ploquin A; Department of Oncology, CHU Lille, F-59000, Lille, France. Turpin A; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. .
Intraductal Papillary Mucinous Carcinoma Versus Conventional Pancreatic Ductal Adenocarcinoma: A Comprehensive Review of Clinical-Pathological Features, Outcomes, and Molecular Insights.
Autorzy:
Mas L; Department of Hepato-Gastroenterology and Digestive Oncology, Pitié Salpêtrière Hospital, APHP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. Lupinacci RM; Department of Digestive and Oncologic Surgery, Ambroise Paré Hospital, AP-HP, 9 Avenue Charles de Gaulle, 92104 Boulogne-Billancourt, France.; UFR des Sciences de la Santé Simone Veil, Versailles St-Quentin-en-Yvelines/Paris Saclay University, 78180 Montigny-le-Bretonneux, France. Cros J; Institut National de la Santé et de la Recherche Médicale-Centre de Recherche Biomédicale Bichat Beaujon (CRI)/INSERM U1149, 92110 Clichy, France.; Department of Pathology, Beaujon Hospital, AP-HP, 100 Boulevard du Général Leclerc, 92110 Clichy, France. BachetJB; Department of Hepato-Gastroenterology and Digestive Oncology, Pitié Salpêtrière Hospital, APHP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France.; Sorbonne University, UPMC University, 75006 Paris, France. Coulet F; Sorbonne University, UPMC University, 75006 Paris, France.; Departement of Genetics, Pitié Salpétrière Hospital, AP-HP, 47-83 Boulevard de l'Hôpital, 75013 Paris, France. Svrcek M; INSERM UMRS_938, Microsatellite Instability and Cancer, Saint-Antoine Research Center, SIRIC CURAMUS, Sorbonne University, 75012 Paris, France.; Department of Pathology, Saint-Antoine Hospital, AP-HP, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France.
Pancreatic Ductal Adenocarcinoma Arising in Young and Old Patients Displays Similar Molecular Features.
Autorzy:
Raffenne J; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France. Martin FA; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Proteomic Research Group, Mediterranean Institute for Life Science, 21000 Split, Croatia. Nicolle R; Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France. Konta M; Proteomic Research Group, Mediterranean Institute for Life Science, 21000 Split, Croatia. Blum Y; Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France. Torrisani J; Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1037, Centre de Recherches en Cancérologie de Toulouse, CEDEX 1, 31 037 Toulouse, France.; Université Toulouse III-Paul Sabatier, CEDEX 9, 31 062 Toulouse, France. Puleo F; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium.; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, 1000 Brussels, Belgium. BachetJB; Department of Gastroenterology, Pitié-Salpetriére Hospital, Sorbonne Universités, UPMC Université, 75013 Paris, France. Svrcek M; Department of Pathology, Saint Antoine Hospital, 75012 Paris, France. Bardier-Dupas A; Department of Pathology, Pitié-Salpetriére Hospital, 75013 Paris, France. Emile JF; Department of Pathology, Ambroise Paré Hospital, 92100 Boulogne-Billancourt, France. Demetter P; Department of Pathology, Erasme Hospital, 1000 Brussels, Belgium. Radman M; Proteomic Research Group, Mediterranean Institute for Life Science, 21000 Split, Croatia. Van Laethem JL; Laboratory of Experimental Gastroenterology and Department of Gastroenterology and Digestive Oncology, Hopital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium. Hammel P; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Department of Medical Oncology, Beaujon Hospital-Université de Paris, 92110 Clichy, France. Rebours V; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Department of Gastroenterology, Beaujon Hospital-Université de Paris, 92110 Clichy, France. Paradis V; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Université de Paris, 92110 Clichy, France. Couvelard A; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Université de Paris, 92110 Clichy, France. Cros J; INSERM U1149, Inflammation Research Center, Beaujon Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Université de Paris, 92110 Clichy, France.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 Mar 11; Vol. 13 (6). Date of Electronic Publication: 2021 Mar 11.
Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021.
Autorzy:
Turpin A; UMR9020-UMR-S 1277 Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000 Lille, France.; Medical Oncology Department, CHU Lille, University of Lille, F-59000 Lille, France. El Amrani M; Department of Digestive Surgery and Transplantation, Lille University Hospital, F-59000 Lille, France. BachetJB; Department of Hepatogastroenterology and GI Oncology, La Pitié-Salpêtrière Hospital, INSERM UMRS 1138, Université de Paris, F-75013 Paris, France. Pietrasz D; Department of Digestive, Oncological, and Transplant Surgery, Paul Brousse Hospital, Paris-Saclay University, F-94800 Villejuif, France. Schwarz L; Department of Digestive Surgery, Rouen University Hospital and Université de Rouen Normandie, F-76100 Rouen, France. Hammel P; Service d'Oncologie Digestive et Médicale, Hôpital Paul Brousse (AP-HP), 12 Avenue Paul Vaillant Couturier, F-94800 Villejuif, France.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2020 Dec 21; Vol. 12 (12). Date of Electronic Publication: 2020 Dec 21.
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Autorzy:
Brouquet A; Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique, Hôpitaux de Paris, 63, rue Gabriel Péri, Le Kremlin Bicetre, 94275, France. .; Faculté de Médecine Paris Sud, Université Paris Saclay, Lrekmlin Bicêtre, 94275, France. . BachetJB; Service d'Oncologie Digestive, Hôpital de la Pitié Salpétrière, Assistance Publique, Hôpitaux de Paris, Paris, 75013, France. Huguet F; Service de Radiothérapie, Hôpital Tenon, Assistance Publique, Hôpitaux de Paris, Paris, 75020, France. Karoui M; Service de Chirurgie Digestive, Hôpital Européen Georges Pompidou, Assistance Publique, Hôpitaux de Paris, Paris, 75015, France. Artru P; Centre d'oncologie Jean Mermoz, Lyon, France. Sabbagh C; Service de Chirurgie Digestive, CHU Amiens, Amiens, 60000, France. Lefèvre JH; Service de Chirurgie Générale et Digestive, Hôpital Saint Antoine, Assistance Publique, Hôpitaux de Paris, Paris, 75012, France. Vernerey D; Unité de recherche clinique CHU, Besançon, France. Mariette C; Service de Chirurgie Digestive et Oncologique, CHU Lille, Lille, 59000, France. Vicaut E; Unité de Recherche Clinique Paris VII, Assistance Publique, Hôpitaux de Paris, Paris, 75010, France. Benoist S; Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre, Groupe Hospitalier Universitaire Paris Sud, Assistance Publique, Hôpitaux de Paris, 63, rue Gabriel Péri, Le Kremlin Bicetre, 94275, France.; Faculté de Médecine Paris Sud, Université Paris Saclay, Lrekmlin Bicêtre, 94275, France.
Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Autorzy:
Schwarz L; Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France. .; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France. . Vernerey D; Methodological and Quality of Life in Oncology Unit, INSERM UMR 1098, University Hospital of Besançon, Besançon, France. BachetJB; Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Paris, France. Tuech JJ; Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France.; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France. Portales F; Department of Digestive Oncology, Institut régional du Cancer de Montpellier (ICM), Val d'Aurelle, Montpellier, France. Michel P; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France.; Department of Hepato-Gastroenterology, Rouen University Hospital, Rouen, France. Cunha AS; Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Paul Brousse Hospital, Villejuif, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Mar 03; Vol. 20 (1), pp. 168. Date of Electronic Publication: 2020 Mar 03.
Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Autorzy:
Lee JS; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Rhee TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Pietrasz D; Université Paris Sorbonne Cité, Centre Universitaire des Saints-Péres, Paris, France. BachetJB; Sorbonne Université, Hôpitaux Universitaires Pitié-Salpétrière, APHP, Paris, France. Laurent-Puig P; University Paris Descertes, UMR-S1147, Paris, France. Kong SY; Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center, Goyang, Korea. Takai E; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. Yachida S; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. Shibata T; Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. Lee JW; Department of Surgery, Hallym University Sacred Heart Hospital, Anyang, Korea. Park HC; Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea. Zang DY; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Jeon K; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Lee J; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Kim M; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Kim HS; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Kang HJ; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. Lee YK; Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Nov 18; Vol. 9 (1), pp. 16971. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji:
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.
Autorzy:
Raffenne J; Institut national de la santé et de la recherche médicale (INSERM) U1149, Inflammation research center, Beaujon's Hospital, 92110 Clichy, France. Nicolle R; Programme Cartes d'Identité des Tumeurs (CIT), Ligue Nationale Contre Le Cancer, 75013 Paris, France. Puleo F; Gastroenterology Department, CHIREC Delta Hospital, 1160 Brussels, Belgium. Le Corre D; Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, 75015 Paris, France. Boyez C; Institut national de la santé et de la recherche médicale (INSERM) U1149, Inflammation research center, Beaujon's Hospital, 92110 Clichy, France. Marechal R; Gastroenterology Department, CHIREC Delta Hospital, 1160 Brussels, Belgium. Emile JF; Department of Pathology, Ambroise Paré Hospital, 92100 Boulogne-Billancourt, France. Demetter P; Department of Pathology, Erasme Hospital, 1000 Brussels, Belgium. Bardier A; Department of Pathology, Pitié-Salpetriére Hospital, 75013 Paris, France. Laurent-Puig P; Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, 75015 Paris, France. de Mestier L; Department of Gastroenterology, Beaujon Hospital-Paris University, 92110 Clichy, France. Paradis V; Institut national de la santé et de la recherche médicale (INSERM) U1149, Inflammation research center, Beaujon's Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Paris University, 92110 Clichy, France. Couvelard A; Institut national de la santé et de la recherche médicale (INSERM) U1149, Inflammation research center, Beaujon's Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Paris University, 92110 Clichy, France. VanLathem JL; Department of Gastroenterology and medical oncology, Erasme Hospital, 1000 Brussels, Belgium. MacKey JR; Medical Oncoloy Cross Cancer Institute, Edmonton, AB T6G 1Z2, Canada. BachetJB; Department of Gastroenterology, Pitié-Salpetrière Hospital, Sorbonne Universités, UPMC Université, 75013 Paris, France. Svrcek M; Dpt of Pathology, Saint Antoine Hospital, 75012 Paris, France. Cros J; Institut national de la santé et de la recherche médicale (INSERM) U1149, Inflammation research center, Beaujon's Hospital, 92110 Clichy, France.; Department of Pathology, Beaujon-Bichat Hospital-Paris University, 92110 Clichy, France.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Nov 18; Vol. 11 (11). Date of Electronic Publication: 2019 Nov 18.
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Autorzy:
Charton E; Methodology and Quality of Life Unit in Oncology, INSERM UMR 1098, University Hospital of Besançon, Besançon, France.; University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France. BachetJB; Department of Hepato-Gastroenterology, Groupe hospitalier Pitié Salpêtrière, Sorbonne University, UPMC University, Paris, France. Hammel P; Department of Digestive Oncology, Hôpital Beaujon, Clichy, France. Desramé J; Department of Hepato-Gastroenterology, Hôpital Privé Jean Mermoz, Lyon, France. Chibaudel B; Department of Oncology, Institut Franco-Britannique, Levallois-Perret, France. Cohen R; Department of Oncology, AP-HP, Hôpital Saint-Antoine, Sorbonne University, Paris, France. Debourdeau P; Department of Oncology, Institut Saint Catherine, Avignon, France. Dauba J; Department of Oncology, Hôpital Layne Mont de Marsan, Mont de Marsan, France. Lecomte T; Department of Hepato-Gastroenterology, Hôpital Trousseau, Tours, France. Seitz JF; CHU La Timone, Marseille, France. Tournigand C; Department of Oncology, CHU Henri Mondor, Créteil, France. Aparicio T; Department of Hepato-Gastroenterology, CHU Saint Louis, Paris, France. Guerin-Meyer V; Department of Oncology, Institut de cancérologie de L'Ouest Paul Papin, Angers, France. Taieb J; Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France. Volet J; Department of Hepato-Gastroenterology, CHU Robert Debré, Reims, France. Louvet C; Department of Oncology, Institut Mutualiste Montsouris, Paris, France. Anota A; Methodology and Quality of Life Unit in Oncology, INSERM UMR 1098, University Hospital of Besançon, Besançon, France.; University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; French National Platform of Quality of Life and Cancer, Besançon, France. Bonnetain F; Methodology and Quality of Life Unit in Oncology, INSERM UMR 1098, University Hospital of Besançon, Besançon, France.; University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; French National Platform of Quality of Life and Cancer, Besançon, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2019 Sep; Vol. 8 (11), pp. 5079-5088. Date of Electronic Publication: 2019 Jul 17.
BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.
Autorzy:
Mas L; Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, 75013 Paris, France.; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France. BachetJB; Department of Hepato-Gastroenterology, Groupe Hospitalier Pitié Salpêtrière, 75013 Paris, France.; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Sorbonne Université, UPMC Université, 75006 Paris, France.; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe labellisée Ligue Nationale Contre le Cancer, 75006 Paris, France. Taly V; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe labellisée Ligue Nationale Contre le Cancer, 75006 Paris, France. Bouché O; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Hepato-Gastroenterology, Hôpital Robert Debré, 51100 Reims, France. Taieb J; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Oncology Digestive, Hôpital Européen Georges Pompidou, 75015 Paris, France. Cohen R; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Sorbonne Université, UPMC Université, 75006 Paris, France.; Department of Oncology, Hôpital Saint-Antoine, 75012 Paris, France. Meurisse A; Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, 25000 Besancon, France. Normand C; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe labellisée Ligue Nationale Contre le Cancer, 75006 Paris, France. Gornet JM; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Saint-Louis, 75010 Paris, France. Artru P; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Privé Jean Mermoz, 69008 Lyon, France. Louafi S; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Centre Hospitalier Sud Francilien, 91100 Corbeil-Essonnes, France.; Department of Gastroenterology, Groupe Hospitalier Nord Essonne, 91160 Longjumeau, France. Thirot-Bidault A; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Kremlin Bicêtre, 94043 Le Kremlin-Bicêtre, France. Baumgaertner I; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Oncology, Hôpital Henri Mondor, 94000 Créteil, France. Coriat R; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Cochin, 75014 Paris, France. Tougeron D; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Depatment of Gastroenterology, Centre Hospitalo-Universitaire de Poitiers, 86000 Poitiers, France. Lecomte T; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Centre Hospitalo-Universitaire de Tours, 37000 Tours, France. Mary F; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Avicenne, 93000 Bobigny, France. Aparicio T; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Department of Gastroenterology, Hôpital Saint-Louis, 75010 Paris, France.; Department of Gastroenterology, Hôpital Avicenne, 93000 Bobigny, France. Marthey L; AGEO (Association des Gastroentérologues Oncologues), 75013 Paris, France.; Depatment of Gastroenterology, Hôpital Antoine Béclère, 92023 Clamart, France. Blons H; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe labellisée Ligue Nationale Contre le Cancer, 75006 Paris, France.; Department of Biochemistry, Hôpital Européen Georges Pompidou, 75015 Paris, France. Vernerey D; Department of Methodology and Quality of Life in Oncology, INSERM UMR 1098, Hôpital Universitaire de Besancon, 25000 Besancon, France. Laurent-Puig P; Université Sorbonne Paris Cité, INSERM UMR-S1147 MEPPOT, CNRS SNC5014, Centre Universitaire des Saints-Pères, Equipe labellisée Ligue Nationale Contre le Cancer, 75006 Paris, France. .
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2019 Jul 17; Vol. 11 (7). Date of Electronic Publication: 2019 Jul 17.
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Autorzy:
Schwarz L; Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France. .; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France. . Vernerey D; Methodological and Quality of Life in Oncology Unit, INSERM UMR 1098, University Hospital of Besançon, Besançon, France. BachetJB; Department of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Paris, France. Tuech JJ; Department of Digestive Surgery, Hôpital Charles Nicolle, Rouen, France.; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France. Portales F; Department of Digestive Oncology, Institut régional du Cancer de Montpellier (ICM) - Val d'Aurelle, Montpellier, France. Michel P; UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie Univ, F-76000, Rouen, France.; Department of Hepato-Gastroenterology, Rouen University Hospital, Rouen, France. Cunha AS; Department of Hepatobiliary and Pancreatic Surgery and Liver Transplantation, Paul Brousse Hospital, Villejuif, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Jul 24; Vol. 18 (1), pp. 762. Date of Electronic Publication: 2018 Jul 24.
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Autorzy:
Kim S; Centre Hospitalier Universitaire de Besançon, Besançon, France. .; Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France. .; INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France. .; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group, Besançon, France. .; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France. .; Department of Oncology, Jean Minjoz University Teaching Hospital, 3 Boulevard Alexander Fleming, F-25030, Besancon, France. . Jary M; Centre Hospitalier Universitaire de Besançon, Besançon, France.; Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France.; INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France.; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group, Besançon, France. André T; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group, Besançon, France.; Hôpital Saint Antoine, Paris, France. Vendrely V; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Buecher B; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.; Institut Curie, Paris, France. François E; Centre Antoine-Lacassagne, Nice, France. Bidard FC; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group, Besançon, France.; Institut Curie, Paris, France. Dumont S; Hôpital Saint Antoine, Paris, France. Samalin E; Institut du Cancer de Montpellier, Montpellier, France. Peiffert D; Institut de Cancérologie de Lorraine, Nancy, France. Pernot S; Hôpital européen Georges-Pompidou, Paris, France. Baba-Hamed N; Groupe Hospitalier Paris Saint-Joseph, Paris, France. El Hajbi F; Centre Oscar Lambret, Lille, France. Bouché O; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.; Centre Hospitalier Universitaire de Reims, Reims, France. Desrame J; Hôpital privé Jean Mermoz, Lyon, France. Parzy A; Centre François Baclesse, Caen, France. Zoubir M; Hôpital Privé des Peupliers, Paris, France. Louvet C; Institut Mutualiste Montsouris, Paris, France. BachetJB; Hôpital Pitié Salpêtrière, Paris, France. Nguyen T; Centre Hospitalier Universitaire de Besançon, Besançon, France.; Polyclique de Franche-Comté, Besançon, France. Abdelghani MB; Centre Paul Strauss, Strasbourg, France. Smith D; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. De La Fouchardière C; Centre Léon Bérard, Lyon, France. Aparicio T; Hôpital Avicenne, Bobigny, France. Bennouna J; Institut de Cancérologie de l'Ouest, Nantes, France. Gornet JM; Hôpital Saint Louis, Paris, France. Jacquin M; Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France.; Cancéropôle Grand Est, Besançon, France. Bonnetain F; INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France.; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.; French National Platform Quality of Life and Cancer, Besançon, France. Borg C; Centre Hospitalier Universitaire de Besançon, Besançon, France.; Clinical Investigational Center, CIC-1431, University Hospital of Besançon, Besançon, France.; INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France.; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) Oncology Multidisciplinary Group, Besançon, France.; Fédération Francophone de Cancérologie Digestive (FFCD), Dijon, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2017 Aug 25; Vol. 17 (1), pp. 574. Date of Electronic Publication: 2017 Aug 25.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Autorzy:
Chibaudel B; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France.; Preclinical and Translational Cancer Research Unit, AAREC Filia Research (AFR), Paris, France. Maindrault-Gœbel F; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France. BachetJB; Department of Gastroenterology, La Pitié-Salpetrière Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France. Louvet C; Department of Medical Oncology, Montsouris Mutualiste Institute, Paris, France. Khalil A; Department of Medical Oncology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France. Dupuis O; Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France. Hammel P; Department of Gastroenterology, Beaujon Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Clichy, France. Garcia ML; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France. Bennamoun M; Department of Medical Oncology, Montsouris Mutualiste Institute, Paris, France. Brusquant D; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France. Tournigand C; Department of Medical Oncology, Henri Mondor Hospital, Créteil, France. André T; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France. Arbaud C; Methodological and quality of life unit in oncology (EA3181) & Quality of life and cancer clinical research platform, CHU Besançon, Besançon, France. Larsen AK; Cancer Biology and Therapeutics, INSERM U938 and Pierre and Marie Curie University, Paris, France. Wang YW; PharmaEngine, Inc., Taipei, Taiwan. Yeh CG; PharmaEngine, Inc., Taipei, Taiwan. Bonnetain F; Methodological and quality of life unit in oncology (EA3181) & Quality of life and cancer clinical research platform, CHU Besançon, Besançon, France. de Gramont A; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2016 Apr; Vol. 5 (4), pp. 676-83. Date of Electronic Publication: 2016 Jan 24.
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Autorzy:
Neuzillet C; INSERM UMR1149.; Department of Digestive Oncology, Beaujon University Hospital, Clichy, France.; Paris 7 Denis Diderot University, Paris, France. Couvelard A; INSERM UMR1149.; Paris 7 Denis Diderot University, Paris, France.; Department of Pathology, Bichat-Beaujon University Hospital, Paris-Clichy, France. Tijeras-Raballand A; Department of Translational Research, AAREC Filia Research, Boulogne-Billancourt, France. de Mestier L; INSERM UMR1149. de Gramont A; Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Bédossa P; INSERM UMR1149.; Paris 7 Denis Diderot University, Paris, France.; Department of Pathology, Bichat-Beaujon University Hospital, Paris-Clichy, France. Paradis V; INSERM UMR1149.; Paris 7 Denis Diderot University, Paris, France.; Department of Pathology, Bichat-Beaujon University Hospital, Paris-Clichy, France. Sauvanet A; Paris 7 Denis Diderot University, Paris, France.; Department of Biliary and Pancreatic Surgery, Beaujon University Hospital, Clichy, France. BachetJB; Department of Gastroenterology, Pitié-Salpêtrière University Hospital, Paris, France. Ruszniewski P; INSERM UMR1149.; Paris 7 Denis Diderot University, Paris, France.; Department of Gastroenterology and Pancreatology, Beaujon University Hospital, Clichy, France. Raymond E; Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Hammel P; INSERM UMR1149.; Department of Digestive Oncology, Beaujon University Hospital, Clichy, France.; Paris 7 Denis Diderot University, Paris, France. Cros J; INSERM UMR1149.; Paris 7 Denis Diderot University, Paris, France.; Department of Pathology, Bichat-Beaujon University Hospital, Paris-Clichy, France.
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2015 Nov; Vol. 67 (5), pp. 664-76. Date of Electronic Publication: 2015 May 12.
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Autorzy:
BachetJB; Paris-Sorbonne University, UPMC University Paris 06, Paris, France. jean-baptiste.bachet@psl.aphp.fr.; Department of hepatogastroenterology, Groupe hospitalier Pitié Salpêtrière, Paris, France. jean-baptiste.bachet@psl.aphp.fr. Chibaudel B; Department of oncology, Hôpital Saint Antoine, Paris, France. . Bonnetain F; Head of methodology and quality of life in oncology department, Hôpital Universitaire de Besancon, EA 3181, Besancon, France. . Validire P; Department of pathology, Institut Mutualiste Montsouris, Paris, France. . Hammel P; Department of digestive oncology, Hôpital Beaujon, Clichy, France. . André T; Paris-Sorbonne University, UPMC University Paris 06, Paris, France. .; Department of oncology, Hôpital Saint Antoine, Paris, France. . Louvet C; Department of oncology, Institut Mutualiste Montsouris, Paris, France. .
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Autorzy:
Portal A; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France. Pernot S; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France. Tougeron D; Department of Gastroenterology, Poitiers University Hospital, Poitiers, France. Arbaud C; Methodological and Quality of Life Unit in Oncology, Quality of Life and Cancer Clinical Research Platform, Besançon University Hospital, Besançon, France. Bidault AT; Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Sud University, Le Kremlin Bicêtre, France. de la Fouchardière C; Department of Medical Oncology, Anticancer Center Leon Berard, Lyon I university, Lyon, France. Hammel P; Department of Digestive Oncology, Hospital Beaujon, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Denis Diderot University, Clichy, France. Lecomte T; Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Tours, UMR CNRS 7192, François-Rabelais University, Tours, France. Dréanic J; Gastroenterology and Endoscopy Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Sorbonne Paris Cité, Paris, France. Coriat R; Gastroenterology and Endoscopy Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Sorbonne Paris Cité, Paris, France. BachetJB; Department of Gastroenterology, La Pitié-Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, UPMC University Paris 06, Paris, France. Dubreuil O; Department of Gastroenterology, La Pitié-Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, UPMC University Paris 06, Paris, France. Marthey L; Department of Hepatogastroenterology and Nutrition, Antoine-Béclère Hospital, Assistance publique-Hôpitaux de Paris (AP-HP), DHU Hepatinov, Clamart, France. Dahan L; Department of Gastroenterology, University Hospital La Timone, Aix-Marseille University, Marseille, France. Tchoundjeu B; Department of Gastroenterology and Digestive Oncology, Orleans Regional Hospital (CHRO), Orleans, France. Locher C; Department of Gastroenterology, Meaux Hospital, Meaux, France. Lepère C; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France. Bonnetain F; Methodological and Quality of Life Unit in Oncology, Quality of Life and Cancer Clinical Research Platform, Besançon University Hospital, Besançon, France. Taieb J; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 29; Vol. 113 (7), pp. 989-95. Date of Electronic Publication: 2015 Sep 15.
Typ publikacji:
Clinical Study; Journal Article; Multicenter Study
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Autorzy:
Svrcek M; Department of Pathology, AP-HP, Hôpitaux Universitaires Est Parisien, Saint-Antoine Hospital, Paris, France; Université Pierre et Marie Curie - Paris 6, Paris, France. Cros J Maréchal R BachetJB Fléjou JF Demetter P
Pokaż więcej
Źródło:
Histopathology [Histopathology] 2015 Feb; Vol. 66 (3), pp. 457-62. Date of Electronic Publication: 2014 Dec 22.
Copy-neutral loss of heterozygosity and chromosome gains and losses are frequent in gastrointestinal stromal tumors.
Autorzy:
Lourenço N; EA4340, Versailles University, Boulogne-Billancourt, France. .; Digestive Oncology Unit, Saint Louis Hospital, APHP, Paris, France. . Hélias-Rodzewicz Z; EA4340, Versailles University, Boulogne-Billancourt, France. .; Department of Pathology, Ambroise Paré Hospital, APHP, 9 Avenue Charles de Gaulle, Boulogne-Billancourt, France. . BachetJB; EA4340, Versailles University, Boulogne-Billancourt, France. jean-baptiste.bachet@psl.aphp.fr.; Digestive Oncology Unit, Pitié Salpétrière Hospital, APHP, Paris, France. jean-baptiste.bachet@psl.aphp.fr. Brahimi-Adouane S; EA4340, Versailles University, Boulogne-Billancourt, France. . Jardin F; Centre Henri Becquerel, INSERM U918, Université de Rouen, Rouen, France. . Tran van Nhieu J; Department of Pathology, Henri Mondor Hospital, APHP, Créteil, France. . Peschaud F; EA4340, Versailles University, Boulogne-Billancourt, France. .; Department of Surgery, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France. . Martin E; Integragen, Evry, France. . Beauchet A; EA4340, Versailles University, Boulogne-Billancourt, France. .; Clinical Research Unit, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France. . Chibon F; Bergonié Institut, INSERM U916, Bordeaux, France. . Emile JF; EA4340, Versailles University, Boulogne-Billancourt, France. .; Department of Pathology, Ambroise Paré Hospital, APHP, 9 Avenue Charles de Gaulle, Boulogne-Billancourt, France. .
Pokaż więcej
Źródło:
Molecular cancer [Mol Cancer] 2014 Nov 06; Vol. 13, pp. 246. Date of Electronic Publication: 2014 Nov 06.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
